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Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active
antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has
poor outcome with standard chemotherapy. Patients and Methods. We retrospectively reviewed HIV-BL treated in the HAART era
with the Magrath regimen (CODOX-M/IVAC±R) at four Canadian centres. Results. Fourteen patients with HIV-BL received at
least one CODOX-M/IVAC±R treatment. Median age at BL diagnosis was 45.5 years, CD4 count 375 cells/mL and HIV viral load
(VL) <50copies/mL. Patients received PCP prophylaxis and G-CSF, 13 received HAART with chemotherapy and 10 rituximab.
There were 63 episodes of toxicity, none fatal, including: bacterial infection, n = 20; grade 3-4 hematologic toxicity, n = 14; febrile
neutropenia, n = 7; oral thrush; and ifosfamide neurological toxicity, n = 1 each. At a median followup of 11.7 months, 12 (86%)
patients are alive and in remission. All 10 patients who received HAART, chemotherapy, and rituximab are alive. CD4 counts and
HIV VL 6 months following BL therapy completion (n = 5 patients) were >250 cells/mL and undetectable, respectively, in 4.
Conclusion. Intensive chemotherapy with CODOX-M/IVAC±R yielded acceptable toxicity and good survival rates in patients with
HIV-associated Burkitt lymphoma receiving HAART.
1.Introduction
Burkitt lymphoma (BL) is a highly aggressive B-cell non-
Hodgkin Lymphoma (NHL) associated with chromosomal
translocations resulting in upregulation of the proto-onco-
gene C-MYC, which drives progression through the cell cycle
[1]. It has an estimated incidence of 1200 patients per year
in the United States [2]. Immunodeﬁciency associated BL is
more commonly seen with human immunodeﬁciency virus
(HIV) infection than other forms of immunodeﬁciency [3]
though its incidence is lowest in patients with a CD4 count
<50cells/mL [4]. NHL accounts for approximately one third
of AIDS-related malignancies and the frequency of BL is 2.4–
20% of HIV-associated NHL [5].
Several trials comparing the outcomes of patients with
HIV-NHL have demonstrated improved outcomes in the
HAART era [6–12]. Since the availability of rituximab (R),
a monoclonal antibody directed against the B cell antigen
CD20, outcomes have improved in HIV-negative B-cell lym-
phoma [13, 14]. In patients with BL or B-cell ALL treated
with the intensive hyper-CVAD regimen; the addition of rit-
uximabwasidentiﬁedinmultivariateanalysisasafavourable
prognostic factor [15]. However, trials assessing the impact2 Advances in Hematology
of rituximab in HIV-related NHL have shown mixed results
[16–18]. An AIDS Malignancy Consortium (AMC) trial of
CHOP versus CHOP-R for HIV-NHL showed a 14% rate
of infectious deaths in the CHOP-R arm versus 2% with
CHOP, oﬀsetting an improvement in lymphoma control
with CHOP-R [17]. However, in this study, HAART use
was not uniform and most infectious deaths occurred in
patients with a CD4 count <50cells/mL. Conversely, a sin-
gle institution review of patients treated with CHOP-like
chemotherapy with or without rituximab for HIV-relat-
ed diﬀuse large B-cell lymphoma (DLBCL) reported that
CHOP-R was feasible in patients receiving HAART and
yielded an overall survival (OS) of 86% at 30 months. This
wassuperiortooutcomesinpatientsreceivingchemotherapy
with HAART but no rituximab (P<0.03), and the only toxic
deaths seen with rituximab were in patients not receiving
HAART [16]. A third study showed a 2-year OS rate of 75%
in patients receiving rituximab with chemotherapy for HIV-
associated NHL [19]. Finally, a recent trial from the AMC
conﬁrmed good tolerance of immunochemotherapy with
or without HAART, though increased infectious deaths in
patients with a CD4 count <50cells/mL remained problem-
atic [20].
In HIV-negative patients with BL, the most successful
treatments are intensive multiagent chemotherapy protocols
given over a short period to circumvent the development of
drug resistance [19, 21–23]. Prior to the HAART era, HIV
patients tolerated standard chemotherapy regimens poorly
[24] and intensive chemotherapy was generally not feasible.
However, a recent study of HIV-BL showed poor outcomes
with standard chemotherapy, underscoring the need for
intensiﬁcation of therapy appropriate to the lymphoma [25].
Since the advent of HAART, intensiﬁcation of chemotherapy
in HIV-infected patients has been possible [26–28].
In 1996, Magrath et al. reported the use of the chemo-
therapyregimenCODOX-M/IVAC,whichyieldedatwo-year
event free survival of 85–92% in patients with BL [29]. In
this study, we reviewed the outcomes of patients with HIV-
associated BL who received intensive chemotherapy with the
Magrath regimen and HAART, with or without rituximab.
2. Patientsand Methods
Patients treated with the Magrath regimen were identiﬁed
from the database of the hematology practices [30]. Patients
from two centers in Toronto, Ontario and two centers
in Vancouver, British Columbia (BC) were included. All
patients had biopsy proven BL and were HIV positive at
lymphoma diagnosis.
Clinical characteristics and details of therapy were ab-
stracted by chart review. Patient demographics, details of
HIV infection and treatment, BL stage, toxicity of therapy,
lymphoma response to therapy, and survival were record-
ed. Patients underwent standard diagnostic and staging
investigations for lymphoma including: history and phys-
ical examination; excisional or core needle biopsy; blood
counts and chemistry; lactate dehydrogenase (LDH) level;
computed tomography of the chest, abdomen, and pelvis;
bone marrow aspiration and biopsy. Data were collected
as to site of lymphomatous involvement and largest mass,
age, sex, Eastern Cooperative Oncology Group (ECOG)
performance status (PS), initial and subsequent treatments,
response to therapy, complications of therapy, and date and
cause of death. Lymphoma diagnosis was determined by
pathologists using standard diagnostic criteria [3] including
identiﬁcation of the t(8;14) and/or C-MYC translocation
by karyotype analysis or ﬂuorescence in situ hybridization
(FISH). Pathology review was performed at the individual
institutions at which the patients received treatment. BL risk
w a sd e ﬁ n e dr e t r o s p e c t i v e l yb yM a g r a t h[ 29] and BC Cancer
Agency criteria [30]. Low risk by Magrath criteria was ≤1
extranodal site of BL involvement; LDH level of ≤350IU/L;
all other patients were considered high risk. Low risk by
BCCA criteria was Ann Arbor stage I, II, or III; bulk <5cm;
normal LDH level; all other patients were considered high
risk.
All patients were treated as high risk. The planned Ma-
grath regimen involved two cycles of chemotherapy repeated
f o rat o t a lo ff o u rt r e a t m e n t s( C O D O X - M± R (treatment
A) followed by IVAC ± R (treatment B), then repeated). All
patients received central nervous system (CNS) prophylaxis
with intrathecal methotrexate (MTX) and cytarabine. One
patient received EPOCH instead of the second IVAC-R treat-
ment because of neurotoxicity from ifosfamide. Chemother-
apy doses and schedules were CODOX-M ± R: cyclophos-
phamide 800mg/m2 intravenously (IV) on days 1 and 2,
doxorubicin 50mg/m2 IV on day 1, vincristine 1.4mg/m2
IV on days 1 and 8, methotrexate (MTX) 6720mg/m2
[29] or 3000mg/m2 IV on day 10 (MTX 3000mg/m2 was
adopted in BC as per BC Cancer Agency guidelines in
2006, the rationale being that 3000mg/m2 MTX consistently
penetrates the blood-brain barrier but may have less toxicity
than higher doses) followed by standard leucovorin rescue
[30]. Rituximab 375mg/m2,w h e ng i v e n ,w a so nd a y8 .
IVAC-R: cytarabine 2000mg/m2 IV every 12 hours on
days 1 and 2, ifosfamide 1500mg/m2 IV given with MESNA
on days 1–5, etoposide 60mg/m2 on days 1–5, rituximab
375mg/m2, if patients received it, was given on day 4.
EPOCH: etoposide 50mg/m2 continuous IV infusion
days 1–4, doxorubicin 10mg/m2 continuous IV infusion
days 1–4, vincristine 0.4mg/m2 continuous IV infusion days
1–4, cyclophosphamide 375mg/m2 IV day 5, prednisone
60mg/m2 orally days 1–5, rituximab 375mg/m2 on day 8.
Rituximab was given according to provincial availability;
this medication was available for all ten BC patients but not
for the four patients treated in Ontario.
FortheﬁrstpatienttreatedinBCandallOntariopatients
(ﬁve patients in total), CNS prophylaxis or treatment was
planned according to the Magrath regimen for high risk
patients. This consisted of two intrathecal injections of
cytarabine 70mg and one injection of MTX 12mg with cycle
A and one MTX 12mg with cycle B [29]. For subsequent
patients from BC (nine patients total), prophylaxis was
planned according to BCCA guidelines, which consisted of
one injection of cytarabine 50mg with cycle A and two
injections of MTX 12mg with cycle B [30]; two additionalAdvances in Hematology 3
injections of cytarabine are generally given when feasible for
a total of eight intrathecal injections.
Adverse events were graded using the National Cancer
Institute Common Toxicity Criteria. Late neutropenia was
deﬁned as an absolute neutrophil count less than 0.5 × 109/L
at 12 weeks or greater following completion of all chem-
otherapy. Complete remission (CR) was deﬁned as the dis-
appearance of all evidence of lymphoma maintained for at
least 4 weeks following the completion of therapy. Partial
remission (PR) was deﬁned as at least a 50% reduction in
the sum of the largest diameters of all measurable lesions at
4 weeks following completion of all therapy. Progression was
deﬁned as the regrowth of previously responding lesions or
the appearance of disease at a new site. Overall survival (OS)
was deﬁned as the time from diagnosis to the time of death
fromanycause.Patientswerecensoredatthelastknowndate
of contact. OS was determined by the Kaplan-Meier method
using SPSS for windows, version 17.0 (SPSS, Chicago, Ill,
USA).
3. HIVCharacteristics
Clinical data collected were HIV risk (sexual, injection
drug use (IDU), etc.), CD4 count and HIV viral load
at lymphoma diagnosis, prior AIDS, coinfection with the
hepatitis B and/or hepatitis C viruses, and HAART use.
HAART was deﬁned as two nucleoside/nucleotide analogues
andatleastoneproteaseinhibitororanonnucleosidereverse
transcriptase inhibitor [31].
This study was performed in accordance with the re-
quirementsoftheInstitutional ResearchEthics Boardateach
centre.
4. Results
Fourteen patients with HIV-associated BL diagnosed be-
tween December 2004 and August 2009 who received at least
one treatment from the Magrath protocol were identiﬁed
[30].PatientswerefromSt.Paul’sHospital,n = 7;Vancouver
General Hospital, n = 3 (Vancouver); St. Michael’s Hospital,
n = 2; Sunnybrook Hospital, n = 2; (Toronto). One patient
had features intermediate between DLBCL and BL according
to the 2008 World Health Organization (WHO) classiﬁca-
tion, including a documented t(8;14) and a proliferation rate
of 80% in the pericardial ﬂuid. The clinical features were
considered to be more in keeping with BL than DLBCL
and he was treated as such. The C-MYC translocation was
conﬁrmedbyFISHforMYCinninepatients,t(8;14)ineight,
andFISHwasunsuccessfulinone.Thet(8;14)wasconﬁrmed
by karyotype analysis in one patient. The t(14;18) or BCL-
2 was negative by: FISH for t(14;18) in four patients; FISH
for BCL-2 in six patients and immunohistochemistry (IHC)
for BCL-2 in three patients (one of these patients had focal
weak positivity for BCL-2 by IHC, which is accepted in the
WHO 2008 classiﬁcation) [3]. The t(14;18) was negative by
karyotype analysis in two patients, and BCL-2 and t(14;18)
were not reported in two patients.
The baseline characteristics of the patients are shown in
Table 1. Median age at BL diagnosis was 45.5 (range 32–56)
years and all patients were male. By Magrath risk criteria
[29],elevenpatientshadhighriskBLandthreewerelowrisk.
By BCCA risk criteria [30], all fourteen patients had high
risk BL. One patient had CNS involvement at BL diagnosis.
One patient receiving the Magrath regimen had an ECOG
performance status of 4 prior to chemotherapy; he improved
dramaticallywithcyclophosphamideadministeredasasingle
agent and the remainder of the Magrath regimen was given
starting on day 7 with a 50% dose reduction of doxorubicin
for an increased bilirubin level as per BCCA guidelines [30].
Two patients with BL not receiving the Magrath reg-
imen as initial therapy over the same time period were
identiﬁed. The ﬁrst had CNS involvement at BL diagnosis,
was obtunded, had several comorbidities, and received
palliation. The second was initially diagnosed as DLBCL
and received EPOCH-R as initial therapy; the diagnosis was
later amended to BL. The lymphoma progressed following
cycle 4 of EPOCH-R, and he was switched to the Magrath
regimen with initial control of BL. However, the lymphoma
progressed within one month of completing the Magrath
regimen, and he received palliative therapy thereafter.
The median CD4 count at BL diagnosis was 375
(range 140–760)cells/mL and HIV viral load <50 (<50–
200000)copies/mL. Ten patients were receiving HAART
at BL diagnosis and 13 received HAART concurrent with
chemotherapy. Ten patients received rituximab with chem-
otherapy and HAART. Seven patients received all four
planned treatments with rituximab, one patient received
three treatments (he declined further therapy and remains
in remission at last followup), and two patients received only
two rituximab treatments (one patient is still on treatment
and in one patient the reason was not clear, but it was
apparently not due to toxicity). Five patients received high
dose MTX at 6720mg/m2 as per the original Magrath
protocol [29], and nine received 3000mg/m2 as per BC
Cancer Agency guidelines [30]. Thirteen patients received
hematopoietic growth factor supportbetweenchemotherapy
cycles with G-CSF.
Six patients did not complete the entire four treatments
of the Magrath regimen: two patients received three treat-
ments (cycles 1A, 1B, and 2A) and four patients received
two treatments (cycles 1A and 1B). Of two patients receiving
three Magrath treatments, one received EPOCH-R instead of
IVAC-R as the fourth treatment because of prior ifosfamide
neurological toxicity. The other did not receive the second
IVAC-R because of concern that there might be diﬃculty
with collection of autologous stem cells for transplantation.
This patient did not go on to transplant and declined further
treatment, but did achieve complete remission and remains
in remission at 27.6 months of followup. Two patients
who received two Magrath treatments received additional
cycles of lower intensity chemotherapy; one had a complete
remissionandonehadnoresponse.Athirdpatientpresented
with CNS involvement and died of progressive BL following
two Magrath treatments. He received eleven intrathecals
in total in Magrath doses (cytarabine 70mg and MTX
12mg). The CSF was positive on only the ﬁrst specimen
in this patient, and all subsequent samples were negative
for BL. Cycle 1B in this patient was complicated by anoxic4 Advances in Hematology
Table 1: Clinical characteristics and initial treatment of 14 patients
with HIV-associated Burkitt lymphoma.
Characteristic n
Age at BL presentation (years)
≤45 7
>45 7
Age in years, median (range)
45.5 (32–56)
Gender
Male 14
BL stage
I2
II 1
III 4
IV 7
Magrath risk1
Low 3
High 11
BCCA risk2
Low 0
High 14
LDH
Normal 6
Increased 8
ECOG PS3
0-1 4
≥25
Extranodal sites
≥17
HIV risk4
Sexual 9
IDU 3
CD4 at BL diagnosis
<200 4
≥200 10
Prior AIDS5
No 13
Yes 1
Coinfections
Hepatitis B
Known negative 9
Known positive 3
Hepatitis C
Known negative 10
Known positive 3
HAART6
No 1
Yes 13
G-CSF
Yes 13
Table 1: Continued.
Characteristic n
Number of cycles of HD-CT
1-2 4
3-4 10
Received rituximab
No 4
Yes 10
1Magrath risk: low risk has ≤1 extranodal site of BL and LDH ≤350IU/L;
all others are high risk.
2BCCA risk: low risk has Ann Arbor stage I, II, or III; bulk <5cm;normal
LDH level; all others are high risk.
3ECOG Performance Status, n = 5 not recorded.
4HIV Risk, n = 2 not recorded.
5Kaposi sarcoma, n = 1.
6HAARTusuallyincludesonenucleosideanalog,oneproteaseinhibitor,and
either a second nucleoside analog or a nonnucleoside reverse transcription
inhibitor (NNRTI).
AIDS: acquired immunodeﬁciency syndrome; BCCA: British Columbia
Cancer Agency; BL: Burkitt lymphoma; ECOG PS: Eastern Cooperative
Oncology Group; G-CSF: granulocyte colony stimulating factor; HIV:
Human Immunodeﬁciency virus; HAART: highly active antiretroviral
therapy; HD-CT: high dose chemotherapy; IDU: injection drug use; LDH:
lactate dehydrogenase; n: number of patients.
brain injury secondary to sepsis, and he received palliation
thereafter. The lymphoma appeared to be responding to
treatment at the time that active therapy was discontinued.
The fourth patient was still on treatment at the time of data
analysis.
Intrathecal prophylaxis or treatment received was as
follows. One patient with positive CSF for BL received eleven
intrathecalinjectionsofchemotherapy(IT)inMagrathdoses
(cytarabine 70mg, MTX 12mg) though the number of
each cytarabine and MTX doses given are uncertain. One
patient received nine IT, with ﬁve cytarabine 50mg and four
MTX 12mg. Three patients received eight IT, two patients
with four cytarabine 70mg and four MTX 12mg, and one
received four each of cytarabine 50mg and MTX 12mg. One
patient received seven IT, with two cytarabine 50mg and ﬁve
MTX 12mg. One patient received ﬁve IT, two cytarabine
50mg, and three MTX 12mg. Three patients received four
IT;onepatientreceivedtwocytarabine50mgcombinedwith
MTX 12mg and four MTX 12mg and two patients each
received two cytarabine 50mg and MTX 12mg. Two patients
received three IT. One received cytarabine 70mg and MTX
12mg, with the number of each uncertain. One received
cytarabine 25mg combined with MTX 9mg (dose reduced
for increased bilirubin level as per BCCA guidelines) then
two MTX 12mg; this patient declined further IT treatments.
Finally, two patients received two IT. Both received two
cytarabine 70mg; one declined further IT treatments and
one died of lymphoma.
Thirteen patients were documented to have received pro-
phylaxis for PCP infection (trimethoprim-sulfamethoxazole,
n = 10; dapsone, n = 2; not speciﬁed, n = 1), eight
for herpes simplex virus/varicella zoster virus (HSV/VZV
(valacyclovir, n = 6; acyclovir, n = 2)), and four for fungal
infections (ﬂuconazole, n = 2; amphotericin B, n = 2). OfAdvances in Hematology 5
Table 2: Treatment-related toxicity in 14 patients with HIV-related Burkitt lymphoma receiving intensive chemotherapy with CODOX-
M/IVAC ± rituximab.
Treatment-related toxicity Grade 1-2 Grade 3-4
n (episodes) n (patients) n (episodes) n (patients)
Bacterial infection1 53 1 5 4
Culture negative febrile neutropenia — — 7 7
Late neutropenia 5 4
Opportunistic infection2 1111
Grade 3 or 4 hematotoxicity — — 14 14
Cardiac syndrome3 —— 1 1
Stomatitis 3 34 ——
Increased liver enzymes 2 2 — —
Skin reaction 1 1 — —
Peripheral neuropathy 1 1 1 1
Hallucinations 1 1 — —
Neurotoxicity from ifosfamide — — 1 1
Chemotherapy dose reductions, delays,
or changes due to toxicity5 —— 5 4
1Included: bacteremia, n = 12 episodes in 7 patients; urinary tract infection, n = 4 in 2 patients; clostridium diﬃcile diarrhea; n = 3 in 3 patients; cellulitis,
n = 1i n1 p a t i e n t .
2Oral thrush in 1 patient, presumed HSV esophagitis in 1 patient.
3Poorly deﬁned cardiac syndrome;possible CHF following day 1 of cycle 1A, requiring admission to the Coronary Care Unit;patientrecovered and completed
treatment modiﬁed for other toxicities.
4In one of these patients the grade was not reported.
5Dose reductions/delays: Vincristine was held in cycle 2 due to severe peripheral neuropathy in one patient. One patient did not receive day 2
cyclophosphamide in cycle 1A due to developing a cardiac syndrome, in this patient cycle 2A was given without incident. One patient presented with
a bilirubin level of 361 (normal < 20) umol/L from BL hepatic inﬁltration. He received dexamethasone 4mgqid (day-1) followed by cyclophosphamide
1000mg/m2 (day1), and by day 6 the bilirubin was 67. He received the remainder of day 1-2 chemotherapy on day 7 (doxorubicin was given at 50% dose for
increased bilirubin as per BCCA guidelines), rituximab on day 8 and high dose MTX on day 15. The bilirubin normalized by day 26. The patient who had a
cardiac syndrome with cycle 1A later developed ifosfamide neurotoxicity with cycle 1B. He received 2 of 5 doses of ifosfamide, 3 of 5 doses of cytarabine, and
completed cycle 1B with day 3–5 etoposide given on days 15–17. For cycle 2B, he received EPOCH-R. One patient receiving full Magrath doses had cycle 2A
high dose MTX delayed by 6 days because of grade 4 neutropenia.
three patients known to be hepatitis B positive, all received
prophylaxis (emtricitabine, n = 2; lamivudine, n = 1).
The toxicity of treatment is shown in Table 2. No fatal
toxic events were observed. The most common grade 3-4
adverse events were bacterial infection, n = 15; hematologic
toxicity, n = 14; febrile neutropenia, n = 7. There were only
twoopportunisticinfections,oralthrushandpresumedHSV
esophagitis.
One patient developed an altered level of conscious-
ness after receiving two doses of ifosfamide. Mental status
returned to normal within 48 hours after ifosfamide was
held, but deteriorated when rechallenged and recovered
fully within 36 hours with administration of methylene
blue [32, 33]. This patient received the EPOCH-R regimen
in substitution for cycle 2B. Two patients had elevated
liver enzymes: one with known hepatitis C coinfection and
the other had involvement of the biliary tract with BL at
presentation. Dose reductions or changes in regimen were
required in three patients because of therapy-related toxicity.
Dose reductions and delays were as follows. Vincristine was
held in cycle 2 due to severe peripheral neuropathy in one
patient. One patient did not receive day 2 cyclophosphamide
in cycle 1A due to developing a cardiac syndrome. In this
patient, cycle 2A was given without incident. This same
patient developed ifosfamide neurotoxicity with cycle 1B.
He received 2 of 5 doses of ifosfamide, 3 of 5 doses of
cytarabine, and completed cycle 1B with day 3–5 etoposide
given on days 15–17. For cycle 2B he received EPOCH-R.
One patient presented with a bilirubin level of 361 (normal
< 20)umol/L from BL hepatic inﬁltration. He received
dexamethasone 4mg four times daily (from day-1) followed
by cyclophosphamide 1000mg/m2 (day 1) and by day 6
the bilirubin was 67. He received the remainder of day 1-2
chemotherapyonday7(doxorubicinwasgivenata50%dose
reduction for increased bilirubin as per BCCA guidelines),
rituximab on day 8, and high dose MTX on day 15. The
bilirubinnormalizedbyday26.Onepatientwhoreceivedfull
Magrath doses of MTX had cycle 2A high dose MTX delayed
by 6 days because of grade 4 neutropenia. Late neutropenia
occurred in ﬁve patients; all responded to administration of
G-CSF.
Toxicity did not appear to occur more frequently accord-
ing to the type of HAART used, for example comparing
protease-inhibitor (PI) based to non-PI-based regimens, the
occurrence of any toxicity, the number of toxic episodes,
peripheral neuropathy, increased liver function tests, and
late neutropenia did not diﬀer between groups, nor did the
requirement for chemotherapy dose reductions. The episode6 Advances in Hematology
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Figure 1: Overall survival of 14 patients with HIV-associated
Burkitt lymphoma receiving CODOX-M/IVAC chemotherapy, 13
with HAART and 10 with rituximab.
of oral thrush, mucositis, and skin reaction (one each),
however, all occurred in patients receiving PI-based HAART.
CD4 counts and HIV VL measurement were available
six months following the completion of chemotherapy in
ﬁve patients; the CD4 count was >250cells/mL and HIV VL
<50copies/mL in four.
5.SurvivalandCausesofDeath
At a median followup of 11.7 (2.0–53.2) months, 12 of 14
patients (86%) are alive and in remission (Figure 1). All 10
patients who received HAART, intensive chemotherapy, and
rituximab are alive. Eleven of 12 survivors had high-risk
BL and 10 had a CD4 count >200cells/mL at BL diagnosis.
There were 2 deaths, at 2.9 and 6.9 months from lymphoma
diagnosis, both from progressive lymphoma. The CD4 count
at BL diagnosis in these patients was 140 and 180cells/mL.
One patient presented with CNS involvement by BL and
received chemotherapy without HAART or rituximab. The
second patient received chemotherapy and HAART but no
rituximab, and received only two cycles of therapy as he
suﬀered anoxic brain injury secondary to sepsis, prompting
a change in direction of care to palliative management. He
ultimately died of progressive BL.
6. Discussion
In recent years, there has been a shift in treatment goals
for patients with HIV-associated NHL. Prior to the HAART
era, infectious deaths occurred frequently, as immunosup-
pression and myelosuppression from HIV made intensive
chemotherapy regimens needed to eﬀectively treat aggressive
lymphomasdiﬃculttodeliverandlower-dosechemotherapy
regimens given with palliative intent were recommended
[24]. In the HAART era, it has become clear that standard
dose chemotherapy for DLBCL [16, 34], and now intensive
regimens for BL can be considered and used with success
[26, 28, 35–37]. In this study, we reviewed 14 HIV-positive
patients with BL treated with CODOX-M/IVAC±R. Most of
our patients were receiving HAART at BL diagnosis and this
was reﬂected in their relatively preserved immune parame-
ters; the median CD4 count was 375cells/mL and HIV VL
<50copies/mL.Previousseries[38]haveshownsomesuccess
with intensive chemotherapy in HIV-associated BL. Wang et
al. compared patients infected with HIV (n = 8 patients)
to HIV-negative patients treated with the same regimen
and found that toxicity from CODOX-M/IVAC was similar
between groups, with similar rates of myelosuppression and
infectious complications to HIV-negative patients [38]. A
recent study of 30 patient receiving CODOX-M/IVAC and
HAART showed a 3-year OS rate of 52% [39]. In addition,
in a recent update from the AMC, 33 patients with HIV-
associated BL were treated with modiﬁed CODOX-M/IVAC-
R in which high dose MTX was given at 3000mg/m2.A ta
median followup of 9 months, the one year OS was 82%
with no treatment related mortality [40]. Similarly, in 29 BL
patients treated with dose-adjusted EPOCH-R, 10 of whom
were HIV-positive, at a median followup of 57 months, the
OS was 100% [41]. Our CR rate of 86% compares favorably
with this experience, as does the projected one and two year
OS of 83% (median followup 11.7 months) and tolerability
of the regimen. The outcomes are similar to those described
in HIV-negative patients with BL [42]. Relapses of BL tend
to occur early, within a few months of diagnosis [43]. At
a median followup of 11.7 months, only two patients died,
both within seven months of diagnosis, and both of BL. Of
the twelve other patients, none have relapsed, though two
are less than six months from BL diagnosis. Moreover, ten
of twelve survivors had high-risk features at presentation by
Magrath criteria and all twelve survivors were high risk by
BCCA criteria, suggesting that this therapeutic approach can
overcome high-risk BL.
The role of immunotherapy with rituximab added to
chemotherapy in HIV-BL has been a topic of discussion,
though updated results from the AMC trial indicate that this
agent can be safely administered concurrently with chem-
otherapy (EPOCH) and HAART, with good outcomes [20].
Our patients received at most four doses of this agent. The
combination of eight doses of rituximab with the hyper-
CVAD regimen in HIV-negative patients with BL was com-
pared to historical patients treated with hyper-CVAD alone.
There was a signiﬁcant reduction in relapse rate favoring
the inclusion of rituximab (7% versus 34%, P = 0.008),
and improved 3-year OS (89% versus 53%, P<0.01) [15].
Eight doses of rituximab have also been combined with an
intensive chemotherapy regimen in a cohort of HIV-positive
and HIV-negative patients with similar results, including a
CR of 88% and 84%, respectively [36]. Whether more than
four doses of rituximab included with short-course high-
intensity chemotherapy such as CODOX-M/IVAC would
confer additional beneﬁt is unknown but may be an area
worthy of future investigation.
In our ten patients receiving rituximab with BL therapy,
the only evidence of additional complications was the occur-
rence of late neutropenia in ﬁve; all responded to G-CSF.Advances in Hematology 7
This complication appears to be rituximab related, as has
been described in HIV-negative patients. Although late
neutropenia appeared to be equally distributed among
patients receiving PI-based versus non-PI-based HAART,
interactionsbetweenantiretroviralagentsandchemotherapy
medicationsresultinginincreasedmarrowtoxicitycannotbe
ruled out [44, 45].
Another toxicity noted in HIV-DLBCL with rituximab
was an increase in herpes virus infections [16]. For HIV-
positive patients receiving rituximab with chemotherapy for
NHL, we recommend HSV/VZV prophylaxis and monitor-
ing for cytomegalovirus reactivation in those with culture
negative fever. Although these measures were documented in
only eight of our BL patients, there was only one presumed
herpes virus infection in the current study. In the AMC trial,
a higher incidence of infectious toxicity was associated with
rituximab in patients with a CD4 count of <50cells/mL [17].
AlthoughnoneofourpatientshadaCD4count<50cells/mL
at BL diagnosis, all ten patients who received rituximab with
intensive chemotherapy and HAART are alive. It should be
noted that rituximab in patients with active Kaposi sarcoma
(KS) may result in severe KS ﬂares [46].
In general, the toxicity of therapy experienced by our
patients, largely bacterial infections, febrile neutropenia and
grade 3-4 bone marrow suppression, was in keeping with
what one would expect in HIV-negative patients receiv-
ing this chemotherapy protocol. Opportunistic infections
occurred in only two patients, oral thrush in one patient
and presumed HSV esophagitis in another. The only HIV-
speciﬁc form of prophylaxis routinely given was for PCP,
which was given regardless of CD4 count, since the CD4
count may decrease on chemotherapy. However, Montoto et
al. documented a CD4 count >200cell/mL and undetectable
HIV VL at six months following the completion of BL
therapy in 58% and 88% of patients, respectively, indicating
goodimmunologicalrecoveryandvirologicalcontroldespite
intensivechemotherapy,andourﬁndingsareinkeepingwith
this [39].
There was a low rate of mucositis in this series, with
two patients experiencing grade 1-2 stomatitis, and a third
patient experiencing stomatitis with the grade not speciﬁed.
Onepatientwastreatedforpresumedgrade3HSVesophagi-
tis, and it is possible that this patient actually had mucositis.
Of note, nine of the 14 patients in this series received high-
dose MTX at 3000mg/m2 [30] as compared to the dose
of 6720mg/m2 used in the original Magrath protocol [29],
and this could have resulted in lower than expected rates
of mucositis. However, the possibility that episodes of grade
3-4 mucositis were not clearly documented and recognized
retrospectively cannot be ruled out.
More than half of patients (8 of 14) received all four
planned Magrath treatments. Of six who received fewer
intensive treatments, only two were due to toxicity. One
patient had ifosfamide neurotoxicity from which he fully
recovered[32,33];hereceivedEPOCH-Rascycle2Bandhad
no evidence of lymphoma at four months. A second patient
suﬀered anoxic brain injury secondary to sepsis and was
subsequently palliated. These results are in contrast to our
experience with HIV-BL in the pre-HAART era; although
not fully documented and formally compared, many of our
patients suﬀered toxic deaths despite suboptimal lymphoma
chemotherapy.
Limitations of this study include its retrospective nature
and small number of patients reviewed. As the study was
nonrandomized, selection bias must be considered, as these
results may not apply to all patients with HIV-BL. The 14
patients reported here, however, were all the HIV-BL seen
over this time period with two exceptions. The ﬁrst had CNS
involvement atBLdiagnosis, averypoor performancestatus,
andreceivedpalliation.Thesecondhadaninitialdiagnosisof
DLBCL made which was later amended to BL; because of the
initial diagnosis, the Magrath regimen was not used as ﬁrst-
linetreatmentandthispatientwasnotincludedforpurposes
of this report. Thus, the patients reported here represent a
reasonably unselected group of HIV-BL seen over this time
period. Even though two patients with HIV-BL during this
period did not receive the Magrath regimen, some who did
receive Magrath did not receive all planned cycles or ritux-
imab and one did not receive HAART, CODOX-M/IVAC
chemotherapy with HAART and rituximab was feasible in
the majority of patients, was well tolerated by most, and
resulted in acceptable lymphoma control and reasonable
immunologicalrecoveryandvirologicalsuppression.Aswith
other NHL in the HAART era [47], our data suggest that the
clinical outcome of BL has improved to the point that it may
be comparable to outcomes in HIV-negative patients with
similar lymphomas [36, 37].
7. Conclusion
In this review of patients with HIV-associated BL treated
with the intensive Magrath (CODOX-M/IVAC) chemother-
apy regimen and HAART, patients had acceptable tolerance
of therapy even when it included rituximab. Of ten patients
who received chemotherapy, rituximab, and HAART, none
has died. Eleven of twelve survivors had high-risk features,
suggesting that this therapeutic approach can overcome
high-riskBL.TheseresultssuggestthatifHIVcontrolisopti-
mized,patientswithHIV-associatedBLwhoreceiveintensive
chemotherapy and rituximab could achieve survival similar
to HIV-negative BL patients without undue therapy-related
toxicity.
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